trending Market Intelligence /marketintelligence/en/news-insights/trending/bqRlJ-nhKB2SWpGGhYoNYA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Merck's Keytruda approved as 1st-line treatment of lung cancer in Japan

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Merck's Keytruda approved as 1st-line treatment of lung cancer in Japan

Japan's Ministry of Health, Labour, and Welfare approved Merck & Co. Inc.'s Keytruda as first- and- second-line treatment of patients with certain types of advanced or recurrent non-small cell lung cancer.

The drug will be manufactured within the country and promoted with Taiho Pharmaceutical Co. Ltd., Merck said.

The drug was also recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use as first-line treatment of metastatic non-small cell lung cancer in adults. Keytruda is already approved for use in melanoma, lung, head and neck cancer in the U.S.